RxDoctor Payments Data

Ashok Vashishta, MD

Internal Medicine · Mt Pleasant, MINPI 1871538025

Payments from drug & device makers

$5,549in general payments, 2019–2025

Across 330 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$747
  • Boehringer Ingelheim$735
  • Lilly USA, LLC$622
  • Novo Nordisk$621
  • Pfizer$401
  • Novartis$309
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,549 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$213,471
Medicare patients
484
Services billed
2,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin179$189,238
EliquisApixaban274$161,770
AustedoDeutetrabenazine21$131,906
JanuviaSitagliptin Phosphate139$122,101
MounjaroTirzepatide65$107,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$86,218
FarxigaDapagliflozin Propanediol81$75,298
OzempicSemaglutide36$53,067
TrulicityDulaglutide43$51,125
XareltoRivaroxaban61$43,563
LinzessLinaclotide53$36,393
Breo ElliptaFluticasone/Vilanterol66$33,777
NuplazidPimavanserin Tartrate13$32,418
MyrbetriqMirabegron43$25,089
Spiriva HandihalerTiotropium Bromide17$22,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$735$189,238179 claims
PfizerEliquis, Abrysvo$401$167,260292 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$622$166,862148 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$181$132,453193 claims
MerckJanuvia$130$122,101139 claims
AstraZenecaFarxiga, Brilinta, Symbicort$747$94,734137 claims
Novo NordiskOzempic$621$53,06736 claims
Johnson & JohnsonXarelto, Invokana$77$50,47872 claims
AbbVieLinzess$137$36,39353 claims
Acadia Pharmaceuticals IncNuplazid$14$32,41813 claims
Astellas Pharma US IncMyrbetriq$49$25,08943 claims
NovartisEntresto$309$21,81426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Mt Pleasant

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →